Catalog No.
Product Name
Application
Product Information
Citations
-
PROTAC Linker
3-(4-Bromobenzoyl)propionic acid serves as a PROTAC linker, facilitating the synthesis of targeted protein degradation compounds. This reagent is essential for creating bifunctional molecules that promote the ubiquitination and subsequent degradation of specific proteins, enabling studies on protein function and regulation. Researchers can utilize this compound in drug discovery and development processes focusing on targeted therapy. -
PROTAC Linker
Methyl 4-hydroxybicyclo[2.2.2]octane-1-carboxylate is a PROTAC linker designed to facilitate the development of Proteolysis Targeting Chimeras (PROTACs). This compound enables selective degradation of target proteins through targeted ubiquitination, playing a crucial role in modulating cellular pathways. Its application in PROTAC synthesis allows researchers to explore innovative therapeutic strategies in cancer and various diseases by harnessing the power of targeted protein degradation. -
PROTAC Linker
4-(2-((tert-Butoxycarbonyl)amino)ethyl)benzoic acid functions as a PROTAC linker, facilitating the construction of proteolysis-targeting chimeras (PROTACs). This compound is instrumental in the development of targeted protein degradation strategies, which have significant implications in cancer research and other fields of therapeutic discovery. Researchers utilize this linker to enhance the specificity and efficacy of PROTACs in modulating protein levels within cellular systems. -
PROTAC Linker
Benzyl (4-hydroxybutyl)carbamate serves as a PROTAC linker designed for the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates the covalent linkage of target proteins to E3 ligases, promoting targeted protein degradation. It is essential for advancing research in targeted therapies and unraveling protein function in cellular processes. -
PROTAC Linker
Cbz-PEG2-prop-1-yne is a versatile PROTAC linker that facilitates the synthesis of proteolysis-targeting chimeras (PROTACs). By connecting target proteins to E3 ligases, this compound enhances targeted protein degradation, making it a valuable tool in the study of protein function and regulation. Its application in drug discovery and development enables researchers to explore novel therapeutic strategies for various diseases. -
PROTAC Linker
Methyl 5-bromo-4-oxopentanoate is a chemical linker designed for use in the development of Proteolysis Targeting Chimeras (PROTACs). This compound plays a crucial role in the synthesis of PROTACs, facilitating the targeted degradation of proteins by recruiting an E3 ligase. It is essential for researchers investigating targeted protein degradation and exploring therapeutic avenues in cancer and other diseases. -
PROTAC Linkers
Thiol-PEG6-alcohol is a poly(ethylene glycol)-based linker designed for use in PROTAC (proteolysis-targeting chimera) synthesis. This compound features a thiol group that facilitates conjugation and linkage with targeted proteins, enhancing the delivery and degradation of specific intracellular proteins. It is a valuable reagent for researchers developing novel PROTACs for targeted protein degradation in therapeutic applications. -
PROTAC Linker
Methyl 1-(5-Bromopyrimidin-2-yl)piperidine-4-carboxylate is a key linker utilized in the design and synthesis of PROTAC (Proteolysis Targeting Chimera) molecules. It facilitates targeted protein degradation by connecting ligand and E3 ligase components in PROTACs. This compound is essential for advancing research in targeted therapies and studying protein interactions and degradation pathways. -
PROTAC Linker
tert-Butyl 4-(azetidin-3-yl)piperazine-1-carboxylate hydrochloride is a versatile PROTAC linker that facilitates the development of proteolysis-targeting chimeras (PROTACs). This compound enhances the selective degradation of target proteins by linking them to E3 ligases, thereby allowing for targeted therapeutic applications. Its utility in PROTAC synthesis supports research in various fields, including cancer biology and drug discovery. -
PROTAC Linker
tert-Butyl N-[3-(hydroxymethyl)cyclobutyl]carbamate serves as a PROTAC linker, facilitating the effective synthesis of proteolysis targeting chimeras (PROTACs). Its unique structural characteristics improve the conjugation efficiency and stability of the resultant PROTACs. This compound is essential for researchers investigating targeted protein degradation and exploring new therapeutic strategies in various disease models. -
Ligands for E3 Ligase
Benzothiazole-CH2(NH-CO-CH2Cl)-CONH-CH2-Ph is a ligand targeting E3 ubiquitin ligase, an essential component of the ubiquitin-proteasome pathway. This compound is designed for use in research applications involving protein degradation and modulation of cellular processes. It can be conjugated to other ligands via a linker to create more complex structures, such as 22-SLF, facilitating the study of E3 ligase interactions and functions. -
Ligands for E3 Ligase
CRBN ligand-83 is a ligand for the CRBN E3 ubiquitin ligase, facilitating targeted protein degradation via the PROTAC (proteolysis-targeting chimera) technology. This compound enhances the recruitment of E3 ligases to specific substrates, enabling efficient ubiquitination and subsequent proteasomal degradation of target proteins. CRBN ligand-83 is a valuable tool in chemical biology research for studying protein function and the development of therapeutics that harness the ubiquitin-proteasome system. -
CRBN Ligand
NH2-MeO-Ph-amide-(2,6-Dioxo-3-Pip) is a ligand that targets Cereblon (CRBN), a key component of the E3 ubiquitin ligase complex. This compound facilitates the synthesis of PROTAC BRD4 Degrader-22, enabling targeted degradation of the BRD4 protein. Its applications include research in the field of protein degradation and regulation of gene expression, providing a valuable tool for studying the role of BRD4 in various biological processes. -
Thalidomide Analogue
Tetrafluoro-thalidomide is a fluorinated analogue of thalidomide, targeting E3 ligases to activate ubiquitination of proteins for subsequent proteolysis. This compound shows potential significance in studying protein degradation pathways and the therapeutic implications of inhibiting or enhancing E3 ligase activity. Its unique fluorinated structure allows for further derivatization, facilitating the exploration of novel compounds in chemical biology and drug development applications. -
Thalidomide Analog
Thalidomide-O-amido-C8-NHBoc is a thalidomide analog featuring an amide linkage, an octyl alkyl chain, and a carbamate protecting group. This compound serves as a valuable tool in the exploration of thalidomide's mechanisms of action and its derivatives' biological activity. It is applicable in research related to anti-inflammatory and immunomodulatory effects, aiding in the development of novel therapeutic strategies. -
Ligands for E3 Ligase
E3 ligase Ligand 65 is a specific ligand for E3 ubiquitin ligases, facilitating targeted protein degradation through the ubiquitin-proteasome pathway. It serves as a crucial intermediate in the synthesis of AZ'3137, which is utilized in various research applications, including studies on protein homeostasis and therapeutic development. This compound aids in advancing the understanding of E3 ligase function and its implications in cellular processes. -
Thalidomide Analog
Thalidomide-4-F,5-Br is a Thalidomide analogue designed to enhance E3 ligase recruitment for the ubiquitination and subsequent degradation of target proteins. This compound exhibits potential biological activity in modulating protein turnover, making it a valuable tool in diverse research applications, including cancer studies and the investigation of cellular signaling pathways. Furthermore, the presence of fluorine and bromine allows for further derivatization, enabling the exploration of new molecular properties and activities. -
Thalidomide Analog
5-Hydrazinyl thalidomide hydrochloride is a thalidomide analog that incorporates a hydrazine moiety, facilitating the development of PROTACs that target E3 ligases for the ubiquitination of specific proteins. This compound serves as a versatile intermediate, offering potential for further derivatization through reactions with a variety of carbonyl groups. Its application in chemical biology research holds promise for advancing therapeutic strategies targeting protein degradation pathways. -
Ligands for E3 Ligase
CRBN ligand-108 is an E3 ubiquitin ligase ligand that targets the cereblon (CRBN) component of the CRL4 E3 ligase complex. This compound facilitates the recruitment of target proteins for ubiquitination and subsequent degradation via the proteasome. CRBN ligand-108 is particularly valuable in the development of PROTACs (proteolysis-targeting chimeras) for targeted protein degradation research applications. Its utility extends to exploring therapeutic strategies in cancer and other diseases by modulating protein levels. -
Ligands for Target Protein for PROTAC
Thalidomide-5-piperazine is a ligand designed for protein-targeted degradation utilizing the PROTAC technology. This compound facilitates the recruitment of E3 ubiquitin ligases to specific target proteins, promoting their ubiquitination and subsequent proteasomal degradation. It is primarily used in research applications focused on studying protein function and modulation within cellular pathways. -
Ligands for Target Protein for PROTAC
Palbociclib-propargyl is a selective ligand for CDK6, designed for use in PROTAC applications. This compound functions through a PEG linker to effectively bind to the CRBN ligand, forming the PROTAC CP-10, which exhibits a DC50 of 2.1 nM for CDK6. Additionally, Palbociclib-propargyl features an alkyne group making it suitable for click chemistry, specifically allowing for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-bearing molecules. This reagent is valuable for advancing research in targeted protein degradation and cancer therapeutics. -
Ligands for Target Protein for PROTAC
(S)-SKBG-1 is a covalent ligand designed for targeting specific proteins in the context of PROTAC applications. Though classified as inactive, it serves an essential role as an assay control to help validate experimental conditions and results. This compound is valuable for researchers investigating the mechanisms of protein degradation and the development of targeted therapeutic strategies. -
Ligands for Target Protein for PROTAC
Tazemetostat de(methyl morpholine)-COOH is a ligand specifically designed for the target protein EZH2, facilitating the synthesis of EZH2 degraders for the PROTAC approach. This compound exhibits significant biological activity by effectively inhibiting cell viability in diffuse large B-cell lymphoma (DLBCL) and various lymphoma subtypes. It serves as a valuable tool for researchers investigating targeted protein degradation and its therapeutic potential in oncology. -
Ligands for Target Protein for PROTAC
PROTAC BRD9-binding moiety 1 hydrochloride is a ligand that selectively binds to the bromodomain protein BRD9, facilitating its targeted degradation through the PROTAC (Proteolysis Targeting Chimeras) mechanism. This compound is instrumental in research focusing on protein degradation pathways and the modulation of BRD9-associated functions in various biological contexts, such as cancer and inflammation. It serves as a valuable tool for studying the therapeutic potential of targeting BRD9 in disease models. -
Ligands for Target Protein for PROTAC
Piperidine-GNE-049-N-Boc is a ligand that targets the dCBP-1 protein, facilitating the development of proteolysis-targeting chimeras (PROTACs). This compound serves as a potent and selective heterobifunctional degrader for the transcriptional co-activators p300 and CBP. It is applicable in research aimed at understanding protein degradation mechanisms and the modulation of gene expression. -
Ligands for Target Protein for PROTAC
Demethyl-RSL3 functions as a ligand for targeted protein degradation through the proteolysis targeting chimera (PROTAC) mechanism. This compound effectively modulates cellular pathways by inducing degradation of specific proteins. Its applications lie primarily in cancer research and the development of novel therapeutic strategies aimed at improving targeted protein degradation efficacy. -
Ligands for Target Protein for PROTAC Chemical
PROTAC CDK9 ligand-1 is a potent ligand for cyclin-dependent kinase 9 (CDK9), facilitating the synthesis of PROTAC (proteolysis-targeting chimera) constructs. This compound is instrumental for targeted protein degradation studies, enabling researchers to modulate CDK9 activity and investigate its role in transcription regulation and cancer biology. PROTAC CDK9 ligand-1 supports the development of innovative therapeutic strategies aimed at selectively degrading unwanted or malfunctioning proteins. -
Ligands for Target Protein for PROTACs
PRMT5 ligand 2 is a selective ligand targeting protein arginine methyltransferase 5 (PRMT5) for use in PROTAC (proteolysis-targeting chimeras) applications. This compound facilitates the targeted degradation of PRMT5, enabling researchers to investigate its role in various cellular processes, including gene regulation and cell signaling. PRMT5 ligand 2 serves as an essential tool for studying PRMT5's biological functions and elucidating potential therapeutic targets in cancer and other diseases. -
Ligands for Target Protein for PROTAC
BMS-1166-N-piperidine-COOH is a ligand designed to target E3 ligase for PROTAC applications. This compound serves as a key component in the synthesis of PD-1/PD-L1 degrader-1, which facilitates the degradation of the PD-1/PD-L1 complex, a crucial immune checkpoint. With a potent PD-1/PD-L1 interaction inhibition demonstrated by an IC50 of 1.4 nM, BMS-1166-N-piperidine-COOH effectively reverses the suppressive effects of the PD-1/PD-L1 pathway on T cell activation, making it valuable for cancer immunotherapy research. -
Ligands for Target Protein for PROTAC
PROTAC IRAK4 ligand-1 is a synthetic ligand specifically designed to target interleukin-1 receptor-associated kinase 4 (IRAK4). This compound plays a critical role in the development of PROTAC IRAK4 degrader-1, facilitating targeted protein degradation. Its primary applications include cancer research and studies investigating inflammatory pathways, making it a valuable tool for researchers exploring IRAK4-related signaling mechanisms. -
Ligands for Target Protein for PROTAC
A-1210477-piperazinyl is a ligand that specifically binds to myeloid cell leukemia 1 (MCL1), serving as a crucial component in PROTAC (proteolysis-targeting chimeras) technology. This compound plays a significant role in targeted protein degradation research, enabling the modulation of MCL1 levels in various cellular contexts. A-1210477-piperazinyl is valuable for studies aimed at understanding MCL1's involvement in cell survival and cancer biology. -
Ligands for Target Protein for PROTAC
CDK2 ligand-2 is a selective ligand targeting cyclin-dependent kinase 2 (CDK2), facilitating the synthesis of PROTAC (proteolysis targeting chimera) molecules. By combining CDK2 ligand-2 with E3 Ligase Ligand-linker Conjugate 184, researchers can create CDK2 degrader 2, a potent tool for targeted protein degradation studies. This compound is valuable for investigating CDK2's role in cell cycle regulation and exploring therapeutic strategies in cancer research. -
Ligands for Target Protein for PROTAC
AR Antagonist 14 is a potent ligand for specific target proteins utilized in PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates the development of targeted protein degraders, allowing for the selective degradation of androgen receptors. AR Antagonist 14 can be effectively combined with VH 101-amide-piperidine-Pip-alkyne to synthesize PROTAC degraders, enhancing research on targeted therapies in cancer and other diseases. -
Ligands for Target Protein for PROTAC
KAL-21404358 is a ligand designed for specific binding to target proteins for use in PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates the targeted degradation of proteins, providing valuable insights into protein function and regulation. Research applications include the study of protein-protein interactions and the development of targeted therapies in cancer and other diseases. KAL-21404358 supports the advancement of innovative approaches in drug discovery and biological research. -
Ligands for Target Protein for PROTAC
PTPN2 ligand 1 is a specific ligand designed for the PTPN2 target protein, facilitating the development of PROTAC (proteolysis-targeting chimeras). This compound plays a crucial role in research applications focused on targeted protein degradation, providing researchers with the means to investigate the functional relevance of PTPN2 in various biological processes. Additionally, it serves as a synthetic precursor for the compound PVD-06, contributing to further studies in protein modulation. -
Ligands for Target Protein for PROTACs
Palbociclib-CH2COOH is a ligand designed for the Target Protein in PROTAC applications. This compound can function as an active control for evaluating the target protein ligand interactions of CPD-39 and CPD-10. Its specificity and binding capacity make it a valuable tool for researchers investigating targeted protein degradation and related pathways. -
Ligands for Target Protein for PROTAC
PXR Ligand 3 is a ligand for the Pregnane X Receptor (PXR), acting as a critical component in the development of PROTAC (Proteolysis Targeting Chimera) molecules. It facilitates the recruitment of E3 ubiquitin ligases, thereby promoting targeted degradation of specific proteins. This compound is valuable in drug discovery and biochemical research, particularly in studies focused on the modulation of PXR activity and the development of PROTAC-based therapeutics. -
Ligands for Target Protein for PROTACs
IRAK4 ligand-12 is a ligand for interleukin-1 receptor-associated kinase 4 (IRAK4), designed for use in PROTAC (proteolysis targeting chimeras) applications. This compound plays a critical role in the selective degradation of IRAK4, thus enabling the modulation of immune response pathways. It is particularly useful in research focused on inflammation and cancer, facilitating studies on targeted protein degradation strategies. IRAK4 ligand-12 can also be utilized in the synthesis of KTX-951, contributing to advancements in therapeutic development. -
Ligands for Target Protein for PROTAC
SHP2 ligand-3 is a ligand specifically designed for the SHP2 target protein, facilitating the synthesis of SHP2 protein degrader-1. This compound serves as an essential tool in targeted protein degradation studies, enabling the selective degradation of SHP2. Its application in PROTAC technology allows researchers to investigate the functional roles of SHP2 in cellular processes and disease mechanisms, supporting drug discovery and development efforts. -
Ligands for Target Protein for PROTAC
BCN-sulfonamide-PEG2-sulfonamide-N-bis(ethanol) serves as a versatile ligand for target proteins in PROTAC applications. This compound incorporates a sulfonamide linker designed to enhance the solubility of linker-conjugates. It is particularly useful in the synthesis of PROTACs aimed at inducing targeted degradation of proteins with potential antitumor activity. -
Ligands for Target Protein for PROTAC
SMARCA2/4-ligand-6 is a small molecule ligand specific for the SMARCA2 and SMARCA4 proteins, facilitating targeted protein degradation via the PROTAC (Proteolysis Targeting Chimeras) technology. This compound can be utilized in the development of PROTACs aimed at studying the roles of these epigenetic regulators in cancer biology and other diseases. SMARCA2/4-ligand-6 is a valuable tool for researchers investigating targeted therapeutic strategies and protein homeostasis. -
Ligands for Target Protein for PROTAC
BTK-IN-39 is a ligand targeting Bruton’s tyrosine kinase (BTK), designed for the synthesis of PROTAC BTK Degrader-11. This compound enables the selective degradation of BTK, facilitating studies on its biological functions and role in disease models, particularly in hematological malignancies. Its application in PROTAC technology allows for innovative approaches to therapeutic intervention by modulating protein levels within cells. -
Ligands for Target Protein for PROTAC
HDAC8-IN-11 is a potent inhibitor of histone deacetylase 8 (HDAC8), a key regulator of gene expression and cellular processes. This compound demonstrates significant biological activity by modulating acetylation levels of histones and non-histone proteins. HDAC8-IN-11 is primarily utilized in research applications focused on targeted protein degradation via PROTAC technology, facilitating the selective degradation of specific proteins in cellular models. -
Ligands for Target Protein for PROTAC
HG-7-85-01-Decyclopropane is a ligand for target proteins utilized in the PROTAC (Proteolysis Targeting Chimera) technology. This compound features the ABL inhibitor moiety and binds to IAP (inhibitor of apoptosis protein) ligands through a linker, enabling the targeted degradation of specific proteins within cells. Its application in research includes elucidating protein function and pathway regulation, making it a valuable tool in cancer biology and therapeutic development. -
Ligands for Target Protein for PROTAC
mTOR ligand 1 is a potent ligand targeting the mechanistic target of rapamycin (mTOR) for use in PROTAC (Proteolysis Targeting Chimera) applications. This compound plays a crucial role in the degradation of mTOR through the ubiquitin-proteasome system, enabling selective modulation of mTOR activity. mTOR ligand 1 is ideal for research involving mTOR signaling pathways and related cellular processes, providing a valuable tool for investigating therapeutic strategies in cancer and metabolic disorders. -
Ligands for Target Protein for PROTAC
SMARCA2/4-ligand-4 acts as a ligand for the SMARCA2 and SMARCA4 proteins, serving as an essential component for the development of Proteolysis Targeting Chimeras (PROTACs). This compound facilitates the targeted degradation of proteins associated with various cellular processes, providing a powerful tool for drug discovery and therapeutic research. SMARCA2/4-ligand-4 is integral to the synthesis of PROTAC SMARCA2/4 degrader-36, enabling investigations into the modulation of oncogenic pathways and protein homeostasis. -
Ligands for Target Protein for PROTAC
Multi Kinase Ligand 4 is a selective ligand designed for the synthesis of PROTACs, specifically PROTAC DB-0646. This compound plays a crucial role in modulating protein degradation pathways, facilitating targeted protein degradation through the ubiquitin-proteasome system. Its applications extend to drug discovery and development in cancer research, enabling investigations into the regulation of kinase activity and potential therapeutic interventions. -
Ligands for Target Protein for PROTAC
SMARCA2 ligand-7 is a specific ligand for SMARCA2, a key protein involved in chromatin remodeling. This compound is designed for use in PROTAC (PROteolysis TArgeting Chimeras) studies, facilitating targeted protein degradation. SMARCA2 ligand-7 enables researchers to investigate the functional roles of SMARCA2 in cellular processes and its potential as a therapeutic target in various diseases. -
Ligands for Target Protein for PROTAC
Demethyl-RSL3-boc is a ligand designed for targeted protein degradation through PROTAC (Proteolysis Targeting Chimeras) technology. This compound effectively interacts with target proteins to facilitate their ubiquitin-mediated degradation, thereby modulating cellular pathways. Demethyl-RSL3-boc is utilized in research applications focused on studying protein dynamics and developing novel therapeutic strategies for various diseases, including cancer. -
Ligands for Target Protein for PROTAC
SMARCA2/4-ligand-1 is a selective ligand for the proteins SMARCA2 and SMARCA4, facilitating targeted protein degradation via PROTAC (Proteolysis Targeting Chimeras) technology. This compound exhibits promising biological activity by promoting the ubquitination and subsequent degradation of these target proteins. It is designed for use in research applications focusing on gene regulation, chromatin remodeling, and the study of protein homeostasis.
